| 5.39 0.07 (1.32%) | 03-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.02  |
1-year : | 7.7 |
| Resists | First : | 6.01 |
Second : | 6.59 |
| Pivot price | 5.47 |
|||
| Supports | First : | 5.07 | Second : | 4.22 |
| MAs | MA(5) : | 5.35 |
MA(20) : | 5.59 |
| MA(100) : | 5.37 |
MA(250) : | 3.8 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 31.8 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 6.88 | Low : | 1.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CMPX ] has closed above bottom band by 36.1%. Bollinger Bands are 41.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.41 - 5.43 | 5.43 - 5.45 |
| Low: | 5.13 - 5.16 | 5.16 - 5.18 |
| Close: | 5.34 - 5.39 | 5.39 - 5.42 |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Thu, 19 Mar 2026
Compass Therapeutics: Potential Here, But Patience Required (NASDAQ:CMPX) - Seeking Alpha
Wed, 18 Mar 2026
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 17 Mar 2026
Compass Therapeutics, Inc. - Common Stock (NQ: CMPX - The Chronicle-Journal
Fri, 13 Mar 2026
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026 - Meyka
Fri, 13 Mar 2026
Is Compass Therapeutics' (CMPX) New ESOP Shelf Offering Reframing Its Equity-Funded R&D Strategy? - Sahm
Sat, 07 Mar 2026
A Look At Compass Therapeutics (CMPX) Valuation After Recent Trial Milestones And FDA Clearance - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 178 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 88.5 (%) |
| Shares Short | 22,360 (K) |
| Shares Short P.Month | 22,990 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -41.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -11.98 |
| PEG Ratio | 0 |
| Price to Book value | 4.89 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|